Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Christine Cripps"'
Autor:
Peter J. O'Dwyer, A. Bapsi Chakravarthy, Patrick J. Flynn, James D. Brierley, Daniel G. Haller, Roger Santala, Nicholas J. Petrelli, David Cella, Cynthia G. Leichman, Al B. Benson, Rashid A. Awan, Mary F. Mulcahy, Christine Cripps, Timothy E. O'Brien, Frank A. Sinicrope, Neal J. Meropol, Joel E. Tepper, James N. Atkins, Bruce J. Giantonio, Jeff A. Sloan, Robert B. Catalano, Edith P. Mitchell, Robert B. Diasio, Elin R. Sigurdson, John R. Weis, Paul J. Catalano, Lynne I. Wagner, Fengmin Zhao, Stanley R. Hamilton
Publikováno v:
Oncologist
Background The addition of bevacizumab to chemotherapy improved outcomes for patients with metastatic colon cancer. E5204 was designed to test whether the addition of bevacizumab to mFOLFOX6, following neoadjuvant chemoradiation and definitive surger
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ded464c4b4064218df454808e97022fc
https://pubmed.ncbi.nlm.nih.gov/31852811
https://pubmed.ncbi.nlm.nih.gov/31852811
Autor:
Kathleen D. Danenberg, Christine Cripps, James A. Martensen, Robert J. Mayer, Thomas Winder, Tyvin A. Rich, Stephen R. Smalley, Wu Zhang, Al B. Benson, Heinz-Josef Lenz, Jacqueline Benedetti, Cathryn Rankin, Charles D. Blanke, Pierre Oliver Bohanes, Karen W. Makar, Cornelia M. Ulrich
Publikováno v:
Clinical Cancer Research. 21:1583-1590
Purpose: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::921456dcc8e00fbbd1ea27cb22d95015
https://doi.org/10.1158/1078-0432.ccr-14-0857
https://doi.org/10.1158/1078-0432.ccr-14-0857
Autor:
Howard John Lim, Anna Tomiak, Timothy R. Asmis, Grzegorz Korpanty, Stephen Welch, Lesley Seymour, Patricia A. Tang, Yoo-Joung Ko, Dongsheng Tu, John R. Goffin, M. Christine Cripps, Haji Chalchal, Ming-Sound Tsao, Thierry Alcindor, Ashley Theis, Derek J. Jonker, Eric X. Chen, Harriet Feilotter, Hagen F. Kennecke
Publikováno v:
Clinical colorectal cancer. 17(3)
Background Oncolytic reovirus pelareorep might preferentially infect and destroy rat sarcoma (RAS)-activated cells, and has preclinical and early clinical activity against colorectal cancer (CRC). Patients and Methods After a 6-patient safety run-in,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0d691c3118a236dc57d05c3a095e9ab
https://pubmed.ncbi.nlm.nih.gov/29653857
https://pubmed.ncbi.nlm.nih.gov/29653857
Autor:
Frances Whiston, Stephen Welch, Daniel Breadner, Derek J. Jonker, James Joseph Biagi, Anne O'Connell, Larry Stitt, Wendy Lam, M. Christine Cripps, Mark Vincent, Paul Klimo
Publikováno v:
Journal of geriatric oncology. 9(6)
Objectives Palliative chemotherapy's role is to prolong survival while minimizing treatment toxicities to preserve or improve quality of life. We have recently published a phase II trial of dose reduced capecitabine in older or frail patients with ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a8b7f531107002d8e5ed705f0dbffcd
https://pubmed.ncbi.nlm.nih.gov/29728308
https://pubmed.ncbi.nlm.nih.gov/29728308
Autor:
Christine Cripps, Horia Marginean, Jean A. Maroun, Derek J. Jonker, Timothy R. Asmis, G. Chiritescu, R. Goel, Rachel Anne Goodwin
Publikováno v:
Clinical colorectal cancer. 17(2)
Background The objective of the present phase I study was to define the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of irinotecan, capecitabine, and oxaliplatin given in combination (IXO regimen) to patients with previously untre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc917963d6fb7a661807cc100436e4bd
https://pubmed.ncbi.nlm.nih.gov/29330005
https://pubmed.ncbi.nlm.nih.gov/29330005
Autor:
Christine Cripps
Publikováno v:
BMJ (Clinical research ed.). 355
During his time at Liverpool University, John David Elliott Edwards spent time as vice president of the Guild of Undergraduates. After qualifying he spent four years at St Paul’s Eye Hospital, at a time of huge outpatient clinics, where he …
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b73887a3d9281ac36bb0ee3211ca987
https://pubmed.ncbi.nlm.nih.gov/27965214
https://pubmed.ncbi.nlm.nih.gov/27965214
Autor:
Malcolm A.S. Moore, Pawel Zalewski, Pablo Cano, Annie Beaudoin, Scot Dowden, Yoo-Joung Ko, Sukhbinder Dhesy-Thind, John Stewart, Christine Cripps, Thuan Do, Muhammad Zulfiqar, Helene Grassin, Sharlene Gill, Wendy Yin Han Lam
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(32)
Purpose The standard of care for second-line therapy in patients with advanced pancreatic cancer after gemcitabine-based therapy is not clearly defined. The CONKO-003 phase III study reported a survival benefit with second-line fluorouracil (FU) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebb442008464a56c9ad59733f22b5bbd
https://pubmed.ncbi.nlm.nih.gov/28113022
https://pubmed.ncbi.nlm.nih.gov/28113022
Autor:
Daniel Adam Breadner, Mark David Vincent, Derek J. Jonker, M. Christine Cripps, Paul Klimo, James Joseph Biagi, Wendy Lam, Anne O'Connell, Frances Whiston, Larry Stitt, Stephen Welch
Publikováno v:
Journal of Clinical Oncology. 36:3564-3564
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fa80fa998b8f574d2f80c02bb42a3fc
https://doi.org/10.1200/jco.2018.36.15_suppl.3564
https://doi.org/10.1200/jco.2018.36.15_suppl.3564
Autor:
Paul Klimo, M. Vincent, Wendy Lam, Anne O'Connell, James Joseph Biagi, F. Whiston, Daniel Breadner, M. Christine Cripps, Derek J. Jonker, Larry Stitt, Stephen Welch
Publikováno v:
Journal of Clinical Oncology. 35:237-237
237 Background: The goal of palliative chemotherapy is to prolong survival and decrease the symptomatic disease burden while minimizing treatment toxicities to preserve or improve quality of life. We recently reported a trial of dose reduced capecita
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bea0b9c5b66523a1e22719399678a3b
https://doi.org/10.1200/jco.2017.35.31_suppl.237
https://doi.org/10.1200/jco.2017.35.31_suppl.237
Autor:
Wendy Lam, Mark Vincent, F. Whiston, Larry Stitt, Derek J. Jonker, Stephen Welch, James Joseph Biagi, Daniel Breadner, Paul Klimo, M. Christine Cripps
Publikováno v:
Journal of Clinical Oncology. 35:745-745
745 Background: Capecitabine (Cape) was initially assessed at a dose of 2500 mg/m2 in young or robust patients that do not represent the population in which oncologists consider Cape monotherapy in advanced colorectal cancer (aCRC). In practice Cape
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d76a3a15888dce9cf9c73be56f75d5b
https://doi.org/10.1200/jco.2017.35.4_suppl.745
https://doi.org/10.1200/jco.2017.35.4_suppl.745